Introduction: The study aimed to evaluate the efficacy and safety of solifenacin in older patients with overactive bladder (OAB). Materials and Methods: Observational data on patients aged ≥70 years and the prescribed flexible dose of solifenacin for OAB were collected at 294 offices of German general practitioners. Baseline and week 12 data included type and severity of OAB symptoms, adverse events, quality of life, and change in cognitive function per Mini Mental State Examination (MMSE). Results: Mean age of 774 patients was 78 ± 6 years. A decrease was observed in all OAB symptoms including a reduction of urinary urgency and micturition, each by 4 episodes per 24 h. No change in mean MMSE scores was apparent at week 12. Adverse events and treatment discontinuations were low at 5.8 and 0.5%, respectively. Conclusion: Solifenacin was well-tolerated while OAB symptoms declined at week 12. No relevant effect of solifenacin on cognitive function was observed in this elderly population.

Keywords:
Cognitive function, Elderly, Overactive bladder symptoms, Solifenacin
1.
Stewart WF, Van Rooyen JB, Cundiff GW, et al: Prevalence and burden of overactive bladder in the United States. World J Urol 2003;20:327-336.
2.
Irwin DE, Milsom I, Hunskaar S, et al: Population-based survey of urinary incontinence, overactive bladder, and other lower urinary tract symptoms in five countries: results of the EPIC study. Eur Urol 2006;50:1306-1314; discussion 1314-1315.
3.
Tune LE: Anticholinergic effects of medication in elderly patients. J Clin Psychiatry 2001;62(suppl 21):11-14.
4.
Kay GG, Abou-Donia MB, Messer WS Jr, Murphy DG, Tsao JW, Ouslander JG: Antimuscarinic drugs for overactive bladder and their potential effects on cognitive function in older patients. J Am Geriatr Soc 2005;53:2195-2201.
5.
Gray SL, Anderson ML, Dublin S, et al: Cumulative use of strong anticholinergics and incident dementia: a prospective cohort study. JAMA Intern Med 2015;175:401-407.
6.
Fox C, Richardson K, Maidment ID, et al: Anticholinergic medication use and cognitive impairment in the older population: the medical research council cognitive function and ageing study. J Am Geriatr Soc 2011;59:1477-1483.
7.
Whalley LJ, Sharma S, Fox HC, et al: Anticholinergic drugs in late life: adverse effects on cognition but not on progress to dementia. J Alzheimers Dis 2012;1:253-261.
8.
Wagg A, Verdejo C, Molander U: Review of cognitive impairment with antimuscarinic agents in elderly patients with overactive bladder. Int J Clin Pract 2010;64:1279-1286.
9.
Wagg A, Wyndaele JJ, Sieber P: Efficacy and tolerability of solifenacin in elderly subjects with overactive bladder syndrome: a pooled analysis. Am J Geriatr Pharmacother 2006;4:14-24.
10.
Lucas MG, Bosch JLHR, Cruz FR, et al: Guidelines on Urinary Incontinence. Uroweb. 2012. http://www.uroweb.org/gls/pdf/18_Urinary_Incontinence_LR_1October2012.pdf (cited July 1, 2015).
11.
Abrams P, Cardozo L, Fall M, et al: The standardisation of terminology of lower urinary tract function: report from the standardisation sub-committee of the International Continence Society. Neurourol Urodyn 2002;21:167-178.
12.
Zinner N, Harnett M, Sabounjian L, Sandage B Jr, Dmochowski R, Staskin D: The overactive bladder-symptom composite score: a composite symptom score of toilet voids, urgency severity and urge urinary incontinence in patients with overactive bladder. J Urol 2005;173:1639-1643.
13.
Folstein MF, Folstein SE, McHugh PR: “Mini-mental state”. A practical method for grading the cognitive state of patients for the clinician. J Psychiatr Res 1975;12:189-198.
14.
Wagg A: Treating overactive bladder in the elderly. Can Urol Assoc J 2011;5(5 suppl 2):S149-S151.
15.
Camões J, Coelho A, Castro-Diaz D, Cruz F: Lower urinary tract symptoms and aging: the impact of chronic bladder ischemia on overactive bladder syndrome. Urol Int 2015;95:373-379.
16.
Wagg AS, Cardozo L, Chapple C, et al: Overactive bladder syndrome in older people. BJU Int 2007;99:502-509.
17.
Lapitan MCM: Epidemiology of urinary incontinence; in Badlani GH, Davila GW, Michel MC, de la Rosette JJMCH (eds): Continence. Current Concepts and Treatment Strategies. Heidelberg, Springer, 2009, pp 3-13.
18.
Madhu C, Enki D, Drake MJ, Hashim H: The functional effects of cigarette smoking in women on the lower urinary tract. Urol Int 2015;95:478-482.
19.
Cardozo L, Hessdorfer E, Milani R, et al: Solifenacin in the treatment of urgency and other symptoms of overactive bladder: results from a randomized, double-blind, placebo-controlled, rising-dose trial. BJU Int 2008;102:1120-1127.
20.
Karram MM, Toglia MR, Serels SR, Andoh M, Fakhoury A, Forero-Schwanhaeuser S: Treatment with solifenacin increases warning time and improves symptoms of overactive bladder: results from VENUS, a randomized, double-blind, placebo-controlled trial. Urology 2009;73:14-18.
21.
Carrière I, Fourrier-Reglat A, Dartigues JF, et al: Drugs with anticholinergic properties, cognitive decline, and dementia in an elderly general population: the 3-city study. Arch Intern Med 2009;169:1317-1324.
22.
Mitchell AJ: A meta-analysis of the accuracy of the mini-mental state examination in the detection of dementia and mild cognitive impairment. J Psychiatr Res 2009;43:411-431.
23.
Chodosh J, Petitti DB, Elliott M, et al: Physician recognition of cognitive impairment: evaluating the need for improvement. J Am Geriatr Soc 2004;52:1051-1059.
24.
Valcour VG, Masaki KH, Curb JD, Blanchette PL: The detection of dementia in the primary care setting. Arch Intern Med 2000;160:2964-2968.
25.
Boustani M, Callahan CM, Unverzagt FW, et al: Implementing a screening and diagnosis program for dementia in primary care. J Gen Intern Med 2005;20:572-577.
26.
Bradford A, Kunik ME, Schulz P, Williams SP, Singh H: Missed and delayed diagnosis of dementia in primary care: prevalence and contributing factors. Alzheimer Dis Assoc Disord 2009;23:306-314.
27.
Cordell CB, Borson S, Boustani M, et al: Alzheimer's association recommendations for operationalizing the detection of cognitive impairment during the Medicare Annual Wellness Visit in a primary care setting. Alzheimers Dement 2013;9:141-150.
28.
Wagg A, Khullar V, Marschall-Kehrel D, et al: Flexible-dose fesoterodine in elderly adults with overactive bladder: results of the randomized, double-blind, placebo-controlled study of fesoterodine in an aging population trial. J Am Geriatr Soc 2013;61:185-193.
29.
Park JW: The effect of solifenacin on cognitive function following stroke. Dement Geriatr Cogn Dis Extra 2013;3:143-147.
30.
Burger M, Betz D, Hampel C, Vogel M: Efficacy and tolerability of solifenacin in men with overactive bladder: results of an observational study. World J Urol 2014;32:1041-1047.
31.
Wesnes KA, Edgar C, Tretter RN, Bolodeoku J: Exploratory pilot study assessing the risk of cognitive impairment or sedation in the elderly following single doses of solifenacin 10 mg. Expert Opin Drug Saf 2009;8:615-626.
32.
Wagg A, Dale M, Tretter R, Stow B, Compion G: Randomised, multicentre, placebo-controlled, double-blind crossover study investigating the effect of solifenacin and oxybutynin in elderly people with mild cognitive impairment: the SENIOR study. Eur Urol 2013;64:74-81.
33.
Watfa G, Husson N, Buatois S, Laurain MC, Miget P, Benetos A: Study of Mini-Mental State Exam evolution in community-dwelling subjects aged over 60 years without dementia. J Nutr Health Aging 2011;15:901-904.
34.
Ridha B, Rossor M: The Mini Mental State Examination. Pract Neurol 2005;5:298-303.
35.
Chapple CR, Rechberger T, Al-Shukri S, et al: Randomized, double-blind placebo- and tolterodine-controlled trial of the once-daily antimuscarinic agent solifenacin in patients with symptomatic overactive bladder. BJU Int 2004;93:303-310.
36.
Michel MC, Wetterauer U, Vogel M, de la Rosette JJ: Cardiovascular safety and overall tolerability of solifenacin in routine clinical use: a 12-week, open-label, post-marketing surveillance study. Drug Saf 2008;31:505-514.
37.
Theobald K, Capan M, Herbold M, Schinzel S, Hundt F: Quality assurance in non-interventional studies. Ger Med Sci 2009;7:29.
38.
Concato J, Shah N, Horwitz RI: Randomized, controlled trials, observational studies, and the hierarchy of research designs. N Engl J Med 2000;342:1887-1892.
39.
Benson K, Hartz AJ: A comparison of observational studies and randomized, controlled trials. N Engl J Med 2000;342:1878-1886.
© 2017 S. Karger AG, Basel
2017
Copyright / Drug Dosage / Disclaimer
Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.
You do not currently have access to this content.